As the world hurried to roll out some sort of offensive weapon against COVID-19, there were some way in the back worried about just how fast is too fast?
You see, there is a large contingent out there in America, (and beyond), who are already skeptical about vaccinations in general. Many feel as though they are an unnecessary risk, and, further, that no government should be able to mandate what people put into their bodies as a principle of sovereignty.
And so there are already worries that vaccine reluctance could slow down our recovery from this dreadful pandemic, as anti-vaccination individuals suggest that the speed in which these jabs were developed could be a red flag for trouble.
The latest issues with the AstraZeneca inoculation certainly aren’t helping the problem.
European and British regulators said on Wednesday they had found possible links between AstraZeneca’s vaccine and very rare cases of blood clots, but reaffirmed its importance in protecting people against COVID-19.
A British government advisory group said the vaccine should not be given to the under 30s where possible, though an official said this was “really out of the utmost caution, rather than because we have any serious safety concerns”.
More than a dozen countries have at one time suspended use of the vaccine, which has been given to tens of millions in Europe. But most have resumed and some, including France, the Netherlands and Germany, have set a minimum age.
Experts continued to push for citizens to be vaccinated, however.
The European Medicines Agency (EMA) received reports of 169 cases of the rare brain blood clot by early April, after 34 million doses had been administered in the European Economic Area, according to Sabine Straus, chair of the EMA’s safety committee. The EEA comprises the 27 EU countries plus Iceland, Norway and Liechtenstein.
In comparison, four women out of 10,000 would get a blood clot from taking oral contraception.
AstraZeneca’s vaccine does have some extremely potent perks, however.
Not only does the shot cost next to nothing thanks to the company selling them at cost, but the jab does not require any of the extraordinarily low storage temperatures of its competitors.
Become an insider!
Sign up for our free email newsletter, and we'll make sure to keep you in the loop.